



FY27 APPROPRIATIONS REQUESTS SUMMARY

1. Fund CDC Lyme & Tick-borne Disease Programs (Request \$74.5M)

Division of Vector-Borne Diseases

National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)

Centers for Disease Control and Prevention (CDC)

U.S. Department of Health and Human Services (HHS)

a) Fully fund the Kay Hagan Tick Act (Request: \$30M)

- Authorized \$150M over 5 years
- \$30M each year:
 - \$10M for the Centers of Excellence for research grants
 - \$20M for States and Tribes with high-risk Lyme disease for prevention and response
- Requires implementation of the National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People
- FY21 \$4M, FY22 \$16M, FY23 \$18.5M, FY24 \$19.5M, FY25 \$19.5M, FY26 House \$19.5M FY26 Senate 20.5M

b) Fund Lyme and Tickborne disease prevention programs (Request: \$40M)

- Bolster critical prevention programs and public awareness efforts
- Develop safer and more effective tick repellents
- Improve TickNET surveillance networks and accurately determine disease burden
- Fund program to improve count for persistent Lyme disease patients
- Support the division's addition of parasitic diseases including tick-borne Babesiosis at no less than \$5M
- FY21 \$16M, FY22 \$20.5M, FY23 \$26M, FY24 \$27M, FY25 \$27M, FY26 House \$27M & FY26 Senate \$29M

c) Fund Alpha-gal Syndrome (AGS) Healthcare Provider Education and Surveillance (Request \$4.5 million)

- Bolster critical healthcare provider education about AGS
- Bolster public awareness efforts
- Improve timely diagnosis, treatment and management of AGS
- Improve count of Alpha-gal syndrome with focus on high or growing prevalence states
- Increase partnerships between local governments and the health, education, community, non-profit, and faith-based sectors in those high-incidence communities
- FY21 \$0, FY22 \$0, FY23 \$0 FY24 \$0, FY25 \$0, FY26 \$0

2. Fund HHS LymeX Innovation Accelerator (Request: \$5M)

Office of the Secretary

U.S. Department of Health and Human Services

- LymeX initiated with \$25M public-private partnership between the Steven and Alexandra Cohen Foundation and HHS
- \$25M provided by the Foundation for prizes, initially for diagnostic research
- Focus has been on diagnostic innovation, though the original vision statement calls for effective treatments that all Americans can afford
- Currently, Phase 4 teams are executing their clinical validation plans, and completing regulatory submissions to the FDA, awarding up to \$3M in prizes.
- \$5M requested for funding federal implementation to fund
- FY21 \$2M Allocated, FY22 \$0, FY23 \$0, FY24 \$5M, FY25 \$5M, FY26 House \$5M & FY26 Senate \$5M

3. Fund NIH NIAID Lyme and Tickborne Disease and Conditions Research (Request: \$135M)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institutes of Health (NIH)

U.S. Department of Health and Human Services

- CDC estimates at least 476,000 (cases) Americans get Lyme disease in the US each year
- Tickborne diseases such as Alpha-gal Syndrome are increasing and the CDC estimates up to 450,000 Americans suffer today from Alpha-gal.
- Only \$103 per patient is allocated toward Lyme funding for NIH NIAID research, which is far less funding than much more rare infectious diseases for Americans:
 - West Nile (1,466 cases) - \$10,231 per patient
 - Malaria (2000 cases) - \$121,000 per patient
- With a decrease in NIH spending, House & Senate included in FY26 “not less than \$110,000,000, an increase of \$10,000,000, for research into Lyme and other Tick-borne diseases”
- FY21 \$96M, FY22 \$119M, FY23 \$99M, FY24 \$122M, FY25 House \$125M+ & FY25 Senate \$125M+, FY26 At least \$110M

4. Fund ARPA-H TICK Clinical Trials Network (Request: \$50M)

Department of Health and Human Services

- Private sector does not fund clinical trials for Lyme and Tick-borne disease therapeutics due to high risk and lack of financial return
- In partnership with industry, HHS agencies and across Office of the Secretary staff divisions
- Building upon existing Lyme and Tick-Borne Disease Clinical Trials Network supported by Steven and Alexandra Cohen Foundation
- For novel therapeutics or repurposed drugs to treat chronic Lyme disease

- New ARPA-H TICK Clinical Trials Network fits ARPA-H model because program is high risk
- FY26 House Appropriations Committee stated “The committee recognizes the value of and encourages ARPA-H to evaluate the potential benefits of supporting research and development projects related to TBD.”
- TICK = Tick-borne Innovation, Collaboration, and Knowledge
- FY21 \$0, FY22 \$0, FY23 \$0 FY24 \$0, FY25 \$0, FY26 \$0

5. Fund Defense Peer-reviewed Tickborne Disease Research (Request: \$9M)

Tick-borne Disease Research Program

Congressionally Directed Medical Research Program

U.S. Department of War (DOW CDMRP TITLE V)

- Unique peer review includes government experts and Lyme and tickborne diseases experts and patients
- Funded just 16% of qualified proposals in FY24, could fund more with additional resources
- FY21 \$7M, FY22 \$7M, FY23 \$7M, FY24 \$7M, FY25 \$0, FY26 House \$7M & FY26 Senate \$0